Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine vs Support in Low-Risk MDS
NCT01338337Phase 2Completed
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
- Start
- Nov 2010
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Asociación Andaluza de Hematología y Hemoterapia. Primary endpoint: Erythroid haematologic response at Day 504. Started Nov 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01338337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338337.